{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:50:23Z","timestamp":1784663423314,"version":"3.55.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"New Giza University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Benign prostatic hyperplasia (BPH) is a prevalent progressive age-related disorder in men, yet its etiopathophysiology remains poorly understood. Current treatments like finasteride (Fin) have limited long-term efficacy, necessitating alternative therapies. Hydroxychloroquine (HCQ), a safe antimalarial agent, possesses anti-inflammatory, immunomodulatory, and antiproliferative activities, however, its therapeutic effect in BPH has not been investigated. Accordingly, we examined its therapeutic potential and underlying mechanisms, alone or combined with Fin, in testosterone-induced BPH in rats. In BPH-induced rats, HCQ markedly reduced prostate weight and index, and PSA, testosterone, dihydrotestosterone, pro-inflammatory cytokines (TNF-\u03b1, \u03ba and IL-6), and the transcription factor \u201cNF-\u03baB\u201d levels, while improving histological abnormalities in epithelial and stromal tissues. HCQ reduced the mRNA expression of AR and ERK1\/2, and decreased the protein levels of EGFR and STAT3. Additionally, HCQ increased the mRNA expression of FOXO1 and promoted apoptosis through both intrinsic and TRAIL-mediated pathways. This was evidenced by the upregulation of pro-apoptotic Bax and the downregulation of anti-apoptotic Bcl-2 and Bcl-XL levels in the intrinsic pathway, as well as the reduction in mRNA expression of DR4 and DR5 in the TRAIL-mediated pathway. Notably, combining HCQ with Fin enhanced these effects. Molecular docking revealed HCQ\u2019s strong interactions with androgen receptor (AR), EGFR, ERK1\/2, FOXO, and TRAIL death receptors (DR4\/DR5), comparable to Fin except for STAT3. Our findings suggest that HCQ modulates BPH progression by targeting STAT3\/FOXO1\/TRAIL and EGFR\/ERK\/AR pathways, offering a promising therapeutic strategy for BPH, either alone or in combination with Fin.<\/jats:p>","DOI":"10.1038\/s41598-025-04267-y","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T09:06:49Z","timestamp":1750410409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hydroxychloroquine modulates the progression of experimentally induced benign prostatic hyperplasia in rats via targeting EGFR\/ERK\/STAT3 and AR\/FOXO1\/TRAIL pathways: computational and in vivo studies"],"prefix":"10.1038","volume":"15","author":[{"given":"Walaa H.","family":"El-Maadawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Hafiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer A.","family":"Tadros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-5030","authenticated-orcid":false,"given":"Sally A.","family":"Fahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidy M.","family":"Ebrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa A.","family":"Fouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin M.","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"4267_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ajur.2017.06.004","volume":"4","author":"KB Lim","year":"2017","unstructured":"Lim, K. B. Epidemiology of clinical benign prostatic hyperplasia. Asian J. Urol. 4, 148 (2017).","journal-title":"Asian J. Urol."},{"key":"4267_CR2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1159\/000496289","volume":"65","author":"S Madersbacher","year":"2019","unstructured":"Madersbacher, S., Sampson, N. & Culig, Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a Mini-Review. Gerontology 65, 458\u2013464 (2019).","journal-title":"Gerontology"},{"key":"4267_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12894-024-01582-w","volume":"24","author":"Z Ye","year":"2024","unstructured":"Ye, Z. et al. Global burden of benign prostatic hyperplasia in males aged 60\u201390 years from 1990 to 2019: results from the global burden of disease study 2019. BMC Urol. 24, 1\u201315 (2024).","journal-title":"BMC Urol."},{"key":"4267_CR4","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.eururo.2006.12.011","volume":"51","author":"G Kramer","year":"2007","unstructured":"Kramer, G., Mitteregger, D. & Marberger, M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?? Eur. Urol. 51, 1202\u20131216 (2007).","journal-title":"Eur. Urol."},{"key":"4267_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bju.15229","volume":"127","author":"CM Devlin","year":"2021","unstructured":"Devlin, C. M., Simms, M. S. & Maitland, N. J. Benign prostatic hyperplasia - what do we know? BJU Int. 127, 389\u2013399 (2021).","journal-title":"BJU Int."},{"key":"4267_CR6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/bmj.39433.670718.AD","volume":"336","author":"TJ Wilt","year":"2008","unstructured":"Wilt, T. J. & N\u2019Dow, J. Benign prostatic hyperplasia. Part 2\u2013management. BMJ 336, 206\u2013210 (2008).","journal-title":"BMJ"},{"key":"4267_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000473774","volume":"29","author":"E Bierhoff","year":"1996","unstructured":"Bierhoff, E. et al. Stromal nodules in benign prostatic hyperplasia. Eur. Urol. 29, 345\u2013354 (1996).","journal-title":"Eur. Urol."},{"key":"4267_CR8","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1073\/pnas.0812666106","volume":"106","author":"P Alonso-Magdalena","year":"2009","unstructured":"Alonso-Magdalena, P. et al. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc. Natl. Acad. Sci. U S A. 106, 2859\u20132863 (2009).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"4267_CR9","doi-asserted-by":"crossref","unstructured":"Tacklind, J., Fink, H. A., Macdonald, R., Rutks, I. & Wilt, T. J. Finasteride for benign prostatic hyperplasia. Cochrane Database of System. Rev. (2010).","DOI":"10.1002\/14651858.CD006015.pub2"},{"key":"4267_CR10","doi-asserted-by":"crossref","unstructured":"Nascimento-Viana, J. B. et al. The \u03b11-adrenoceptor-mediated human hyperplastic prostate cells proliferation is impaired by EGF receptor Inhibition. Life Sci 239, 145 (2019).","DOI":"10.1016\/j.lfs.2019.117048"},{"key":"4267_CR11","doi-asserted-by":"crossref","unstructured":"Park, W. Y. et al. Ellagic acid improves benign prostate hyperplasia by regulating androgen signaling and STAT3. Cell Death Dis 13, 412 (2022).","DOI":"10.1038\/s41419-022-04995-3"},{"key":"4267_CR12","doi-asserted-by":"crossref","unstructured":"Elbaz, E. M., Darwish, A., Gad, A. M., Abdel Rahman, A. A. S. & Safwat, M. H. Canagliflozin alleviates experimentally induced benign prostate hyperplasia in a rat model: exploring potential mechanisms involving mir-128b\/EGFR\/EGF and JAK2\/STAT3 signaling pathways through in Silico and in vivo investigations. Eur J. Pharmacol 957, 179553 (2023).","DOI":"10.1016\/j.ejphar.2023.175993"},{"key":"4267_CR13","doi-asserted-by":"publisher","first-page":"19942","DOI":"10.1002\/jcp.28592","volume":"234","author":"Z Ke","year":"2019","unstructured":"Ke, Z. et al. Identification of key genes and pathways in benign prostatic hyperplasia. J. Cell. Physiol. 234, 19942\u201319950 (2019).","journal-title":"J. Cell. Physiol."},{"key":"4267_CR14","doi-asserted-by":"crossref","unstructured":"Du, W., Wang, T., Zhang, W., Xiao, Y. & Wang, X. Genetically supported causality between benign prostate hyperplasia and urinary bladder neoplasms: a Mendelian randomization study. Front Genet 13, 1016696 (2022).","DOI":"10.3389\/fgene.2022.1016696"},{"key":"4267_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ajur.2019.10.003","volume":"7","author":"RE Vickman","year":"2020","unstructured":"Vickman, R. E. et al. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: a review. Asian J. Urol. 7, 191\u2013202 (2020).","journal-title":"Asian J. Urol."},{"key":"4267_CR16","doi-asserted-by":"crossref","unstructured":"El-Shafei, N. H., Zaafan, M. A., Kandil, E. A. & Sayed, R. H. Simvastatin ameliorates testosterone-induced prostatic hyperplasia in rats via modulating IGF-1\/PI3K\/AKT\/FOXO signaling. Eur J. Pharmacol 950, 175762 (2023).","DOI":"10.1016\/j.ejphar.2023.175762"},{"key":"4267_CR17","doi-asserted-by":"crossref","unstructured":"Sciacqua, L. V. et al. Minimally invasive treatment in benign prostatic hyperplasia (BPH). Technol Cancer Res. Treat 22, 1533 (2023).","DOI":"10.1177\/15330338231155000"},{"key":"4267_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4103\/0378-6323.51273","volume":"75","author":"P Mansouri","year":"2009","unstructured":"Mansouri, P., Farshi, S. & Safar, F. Finasteride-induced gynecomastia. Indian J. Dermatol. Venereol. Leprol. 75, 309 (2009).","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"4267_CR19","doi-asserted-by":"publisher","first-page":"luae050","DOI":"10.1210\/jcemcr\/luae050","volume":"2","author":"HS Farkas","year":"2024","unstructured":"Farkas, H. S., Jee, Y. H., Szymczuk, V. & Leschek, E. W. Persistent gynecomastia due to Short-term Low-dose finasteride for androgenetic alopecia. JCEM Case Rep. 2, luae050 (2024).","journal-title":"JCEM Case Rep."},{"key":"4267_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199701233360412","volume":"336","author":"J Ohn","year":"1997","unstructured":"Ohn, J. et al. Terazosin, finasteride, or both in benign prostatic hyperplasia. N. Engl. J. Med. 336, 293\u2013294 (1997).","journal-title":"N. Engl. J. Med."},{"key":"4267_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12301-024-00451-0","volume":"30","author":"A Basiri","year":"2024","unstructured":"Basiri, A. et al. Comparison of combination therapy with Tamsulosin and dutasteride or finasteride in patients with benign prostatic hyperplasia: a randomized clinical trial. Afr. J. Urol. 30, 1\u20137 (2024).","journal-title":"Afr. J. Urol."},{"key":"4267_CR22","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.2174\/1381612826666200707132920","volume":"26","author":"GP Martinez","year":"2020","unstructured":"Martinez, G. P., Zabaleta, M. E., Di Giulio, C., Charris, J. E. & Mijares, M. R. The role of chloroquine and hydroxychloroquine in immune regulation and diseases. Curr. Pharm. Des. 26, 4467\u20134485 (2020).","journal-title":"Curr. Pharm. Des."},{"key":"4267_CR23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1089\/omi.2024.0061","volume":"28","author":"S Yanar","year":"2024","unstructured":"Yanar, S., Bal Albayrak, M. G., Kasap, M. & Akpinar, G. From androgen dependence to independence in prostate cancer: unraveling therapeutic potential and proteomic landscape of hydroxychloroquine as an autophagy inhibitor. OMICS 28, 246\u2013255 (2024).","journal-title":"OMICS"},{"key":"4267_CR24","unstructured":"HCQ in Resectable Localized Prostate Cancer\u2014Clinical Tr. https:\/\/clinicaltrial.be\/en\/details\/447845?per_page=20&only_recruiting=0&only_eligible=0&only_active=0 (2023)."},{"key":"4267_CR25","unstructured":"Hydroxychloroquine in treating patients with rising PSA levels after local therapy for prostate cancer | smart patients. https:\/\/www.smartpatients.com\/trials\/NCT00726596 (2024)."},{"key":"4267_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier, E. & D\u00f6rner, T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat. Rev. Rheumatol. 16, 155\u2013166 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"4267_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/S00210-024-03417-9","author":"VC Sangamesh","year":"2024","unstructured":"Sangamesh, V. C., Alagundagi, D. B., Jayaswamy, P. K., Kuriakose, N. & Shetty, P. Targeting AnxA2-EGFR signaling: hydroxychloroquine as a therapeutic strategy for bleomycin-induced pulmonary fibrosis. Naunyn Schmiedebergs Arch. Pharmacol. https:\/\/doi.org\/10.1007\/S00210-024-03417-9 (2024).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"4267_CR28","doi-asserted-by":"crossref","unstructured":"Lyu, X. et al. Hydroxychloroquine suppresses lung tumorigenesis via inducing FoxO3a nuclear translocation through STAT3 inactivation. Life Sci 246, 117366 (2020).","DOI":"10.1016\/j.lfs.2020.117366"},{"key":"4267_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.virol.2020.12.006","volume":"555","author":"SA More","year":"2021","unstructured":"More, S. A., Patil, A. S., Sakle, N. S. & Mokale, S. N. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs. Virology 555, 10\u201318 (2021).","journal-title":"Virology"},{"key":"4267_CR30","doi-asserted-by":"crossref","unstructured":"Chen, J., Pan, Q., Bai, Y., Chen, X. & Zhou, Y. Hydroxychloroquine induces apoptosis in cholangiocarcinoma via reactive oxygen species accumulation induced by autophagy Inhibition. Front Mol. Biosci 8, 720370 (2021).","DOI":"10.3389\/fmolb.2021.720370"},{"key":"4267_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kjms.2017.01.004","volume":"33","author":"YC Lin","year":"2017","unstructured":"Lin, Y. C. et al. Chloroquine and hydroxychloroquine inhibit bladder cancer cell growth by targeting basal autophagy and enhancing apoptosis. Kaohsiung J. Med. Sci. 33, 215\u2013223 (2017).","journal-title":"Kaohsiung J. Med. Sci."},{"key":"4267_CR32","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1159\/000507795","volume":"104","author":"ST Ling","year":"2020","unstructured":"Ling, S. T. et al. Hydroxychloroquine blocks autophagy and promotes apoptosis of the prostate after castration in rats. Urol. Int. 104, 968\u2013974 (2020).","journal-title":"Urol. Int."},{"key":"4267_CR33","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s10787-020-00743-1","volume":"28","author":"EM Elbaz","year":"2020","unstructured":"Elbaz, E. M., Amin, H. A. A., Kamel, A. S., Ibrahim, S. M. & Helmy, H. S. Immunomodulatory effect of Diallyl sulfide on experimentally-induced benign prostate hyperplasia via the suppression of CD4\u2009+\u2009T\/IL-17 and TGF-\u03b21\/ERK pathways. Inflammopharmacology 28, 1407\u20131420 (2020).","journal-title":"Inflammopharmacology"},{"key":"4267_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.taap.2016.09.024","volume":"311","author":"RH Sayed","year":"2016","unstructured":"Sayed, R. H., Saad, M. A. & El-Sahar, A. E. Dapoxetine attenuates testosterone-induced prostatic hyperplasia in rats by the regulation of inflammatory and apoptotic proteins. Toxicol. Appl. Pharmacol. 311, 52\u201360 (2016).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"4267_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12301-021-00137-x","volume":"27","author":"F Akbari","year":"2021","unstructured":"Akbari, F. et al. Evaluation of Juniperus communis L. seed extract on benign prostatic hyperplasia induced in male Wistar rats. Afr. J. Urol. 27, 1\u201311 (2021).","journal-title":"Afr. J. Urol."},{"key":"4267_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248\u2013254 (1976).","journal-title":"Anal. Biochem."},{"key":"4267_CR37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u2206\u2206CT method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"4267_CR38","doi-asserted-by":"publisher","first-page":"46265","DOI":"10.1074\/jbc.M207135200","volume":"277","author":"J Stamos","year":"2002","unstructured":"Stamos, J., Sliwkowski, M. X. & Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277, 46265\u201346272 (2002).","journal-title":"J. Biol. Chem."},{"key":"4267_CR39","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nchembio.1629","volume":"10","author":"A Chaikuad","year":"2014","unstructured":"Chaikuad, A. et al. A unique inhibitor binding site in ERK1\/2 is associated with slow binding kinetics. Nat. Chem. Biol. 10, 853\u2013860 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"4267_CR40","doi-asserted-by":"publisher","first-page":"11004","DOI":"10.1021\/acs.jmedchem.9b01295","volume":"62","author":"RA Ward","year":"2019","unstructured":"Ward, R. A. et al. Discovery of a potent and selective oral inhibitor of ERK1\/2 (AZD0364) that is efficacious in both monotherapy and combination therapy in models of nonsmall cell lung Cancer (NSCLC). J. Med. Chem. 62, 11004\u201311018 (2019).","journal-title":"J. Med. Chem."},{"key":"4267_CR41","doi-asserted-by":"crossref","unstructured":"Hur, E. et al. Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol 2, e274 (2004).","DOI":"10.1371\/journal.pbio.0020274"},{"key":"4267_CR42","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","volume":"36","author":"L Bai","year":"2019","unstructured":"Bai, L. et al. A potent and selective Small-Molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell. 36, 498\u2013511e17 (2019).","journal-title":"Cancer Cell."},{"key":"4267_CR43","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.str.2008.06.013","volume":"16","author":"MM Brent","year":"2008","unstructured":"Brent, M. M., Anand, R. & Marmorstein, R. Structural basis for DNA recognition by FoxO1 and its regulation by posttranslational modification. Structure 16, 1407\u20131416 (2008).","journal-title":"Structure"},{"key":"4267_CR44","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1107\/S2053230X15016416","volume":"71","author":"V Ramamurthy","year":"2015","unstructured":"Ramamurthy, V. et al. The structure of the death receptor 4-TNF-related apoptosis-inducing ligand (DR4-TRAIL) complex. Acta Crystallogr. F Struct. Biol. Commun. 71, 1273\u20131281 (2015).","journal-title":"Acta Crystallogr. F Struct. Biol. Commun."},{"key":"4267_CR45","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/14935","volume":"6","author":"J Mongkolsapaya","year":"1999","unstructured":"Mongkolsapaya, J. et al. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat. Struct. Biol. 6, 1048\u20131053 (1999).","journal-title":"Nat. Struct. Biol."},{"key":"4267_CR46","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk, D. et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638\u2013D646 (2023).","journal-title":"Nucleic Acids Res."},{"key":"4267_CR47","doi-asserted-by":"crossref","unstructured":"Wang, S., He, W., Li, W., Zhou, J. R. & Du, Z. Combination of lycopene and curcumin synergistically alleviates testosterone-propionate-induced benign prostatic hyperplasia in sprague dawley rats via modulating inflammation and proliferation. Molecules 28, 4900 (2023).","DOI":"10.3390\/molecules28134900"},{"key":"4267_CR48","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jn\/133.2.516","volume":"133","author":"JR Zhou","year":"2003","unstructured":"Zhou, J. R., Yu, L., Zhong, Y. & Blackburn, G. L. Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. J. Nutr. 133, 516\u2013521 (2003).","journal-title":"J. Nutr."},{"key":"4267_CR49","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1159\/000517925","volume":"105","author":"A Gul","year":"2021","unstructured":"Gul, A., Zengin, S., Dundar, G. & Ozturk, M. Do SARS-CoV-2 infection (COVID-19) and the medications administered for its treatment impair testicular functions?? Urol. Int. 105, 944\u2013948 (2021).","journal-title":"Urol. Int."},{"key":"4267_CR50","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/humupd\/dmaa022","volume":"26","author":"LF Perez-Garcia","year":"2020","unstructured":"Perez-Garcia, L. F. et al. The effect of paternal exposure to immunosuppressive drugs on sexual function, reproductive hormones, fertility, pregnancy and offspring outcomes: a systematic review. Hum. Reprod. Update. 26, 961\u20131001 (2020).","journal-title":"Hum. Reprod. Update"},{"key":"4267_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41391-020-00277-1","volume":"24","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Animal models of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 24, 49\u201357 (2021).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"4267_CR52","doi-asserted-by":"crossref","unstructured":"Lee, G. et al. Cynanchum wilfordii ameliorates testosterone-induced benign prostatic hyperplasia by regulating 5\u03b1-reductase and androgen receptor activities in a rat model. Nutrients 9, 4900 (2017).","DOI":"10.3390\/nu9101070"},{"key":"4267_CR53","doi-asserted-by":"crossref","unstructured":"Ahmed, R., Hamdy, O. & Awad, R. M. Diagnostic efficacy of systemic immune-inflammation biomarkers in benign prostatic hyperplasia using receiver operating characteristic and artificial neural network. Sci. Rep. 13, 1\u201310  (2023).","DOI":"10.1038\/s41598-023-41781-3"},{"key":"4267_CR54","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2605.2009.00972.x","volume":"33","author":"B Fibbi","year":"2010","unstructured":"Fibbi, B., Penna, G., Morelli, A., Adorini, L. & Maggi, M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int. J. Androl. 33, 475\u2013488 (2010).","journal-title":"Int. J. Androl."},{"key":"4267_CR55","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0022-5347(17)40253-9","volume":"143","author":"GL Morris","year":"1990","unstructured":"Morris, G. L. & Dodd, J. G. Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J. Urol. 143, 1272\u20131274 (1990).","journal-title":"J. Urol."},{"key":"4267_CR56","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1007\/s11033-022-07331-2","volume":"49","author":"T Schmidt","year":"2022","unstructured":"Schmidt, T. S-Adenosylmethionine affects ERK1\/2 and STAT3 pathway in androgen-independent prostate cancer cells. Mol. Biol. Rep. 49, 4805\u20134817 (2022).","journal-title":"Mol. Biol. Rep."},{"key":"4267_CR57","doi-asserted-by":"crossref","unstructured":"Wei, P. et al. Cryptotanshinone modulates proliferation, apoptosis, and fibrosis through inhibiting AR and EGFR\/STAT3 axis to ameliorate benign prostatic hyperplasia progression. Eur J. Pharmacol 938, (2023).","DOI":"10.1016\/j.ejphar.2022.175434"},{"key":"4267_CR58","doi-asserted-by":"publisher","first-page":"614","DOI":"10.7150\/ijbs.8389","volume":"10","author":"Y Zhao","year":"2014","unstructured":"Zhao, Y., Tindall, D. J. & Huang, H. Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer. Int. J. Biol. Sci. 10, 614\u2013619 (2014).","journal-title":"Int. J. Biol. Sci."},{"key":"4267_CR59","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/pros.21162","volume":"70","author":"H Zhang","year":"2010","unstructured":"Zhang, H. et al. Activation of FOXO1 is critical for the anticancer effect of Methylseleninic acid in prostate Cancer cells. Prostate 70, 1265 (2010).","journal-title":"Prostate"},{"key":"4267_CR60","doi-asserted-by":"publisher","first-page":"e15627","DOI":"10.1371\/journal.pone.0015627","volume":"5","author":"S Ganapathy","year":"2010","unstructured":"Ganapathy, S., Chen, Q., Singh, K. P., Shankar, S. & Srivastava, R. K. Resveratrol enhances antitumor activity of TRAIL in prostate Cancer xenografts through activation of FOXO transcription factor. PLoS One. 5, e15627 (2010).","journal-title":"PLoS One"},{"key":"4267_CR61","doi-asserted-by":"publisher","first-page":"47928","DOI":"10.1074\/jbc.M207509200","volume":"277","author":"V Modur","year":"2002","unstructured":"Modur, V., Nagarajan, R., Evers, B. M. & Milbrandt, J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J. Biol. Chem. 277, 47928\u201347937 (2002).","journal-title":"J. Biol. Chem."},{"key":"4267_CR62","doi-asserted-by":"crossref","unstructured":"Stamos, J., Sliwkowski, M. X. & Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277, 46265 (2002).","DOI":"10.1074\/jbc.M207135200"},{"key":"4267_CR63","doi-asserted-by":"crossref","unstructured":"Chaikuad, A. et al. A unique inhibitor binding site in ERK1\/2 is associated with slow binding kinetics. Nat Chem. Biol 10, 853 (2014).","DOI":"10.1038\/nchembio.1629"},{"key":"4267_CR64","doi-asserted-by":"crossref","unstructured":"Bai, L. et al. A potent and selective Small-Molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell 36, 498 (2019).","DOI":"10.1016\/j.ccell.2019.10.002"},{"key":"4267_CR65","doi-asserted-by":"crossref","unstructured":"Brent, M. M., Anand, R. & Marmorstein, R. Structural basis for DNA recognition by FoxO1 and its regulation by posttranslational modification. Structure 16, 1407 (2008).","DOI":"10.1016\/j.str.2008.06.013"},{"key":"4267_CR66","first-page":"1273","volume":"71","author":"V Ramamurthy","year":"2015","unstructured":"Ramamurthy, V. et al. The structure of the death receptor 4-TNF-related apoptosis-inducing ligand (DR4-TRAIL) complex. Acta Crystallogr. Section:F Struct. Biology Commun. 71, 1273\u20131281 (2015).","journal-title":"Acta Crystallogr. Section:F Struct. Biology Commun."},{"key":"4267_CR67","doi-asserted-by":"crossref","unstructured":"Mongkolsapaya, J. et al. Structure of the TRAIL-DR5complex reveals mechanisms conferring specificity in apoptotic initiation, vol. 6. http:\/\/structbio.nature.com  (1999).","DOI":"10.2210\/pdb1d4v\/pdb"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04267-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04267-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04267-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T21:02:22Z","timestamp":1750798942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04267-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4267"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-04267-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20118"}}